Amgen has reported positive Phase 3 results for its subcutaneous formulation of Tepezza, with a notable 77% proptosis response rate in patients with moderate-to-severe thyroid eye disease (TED). This victory positions Amgen favorably against competitors like Viridian Therapeutics, whose stock has faltered in the wake of Amgen's announcement. The shift to subcutaneous delivery could redefine treatment protocols, expanding patient accessibility, while Amgen simultaneously navigates challenges related to drug pricing pressures and increasing biosimilar competition.
“Amgen's SC Tepezza posts late-stage win in thyroid eye disease $AMGN”
“President Trump is doing what they said was impossible, forcing real drug price cuts for everyday Americans. TrumpRx now covers 61+ popular drugs at a fraction of the cost, with major players like AbbVie, Genentech, and Amgen all coming to the table with steep discounts!”
“Amgen/Sanofi - Pharma and AI jobs. This will be emergence of demand for the niche skills (core) that was left behind with the IT wave in the past.”
“$VRDN | Viridian Therapeutics drops after Amgen reports strong Phase 3 results for its thyroid eye disease treatment. Amgen’s success raises competition concerns for Viridian’s pipeline, pressuring the stock.”
“$AMGN - AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR SUBCUTANEOUS TEPEZZA® IN ADULTS LIVING WITH MODERATE-TO-SEVERE ACTIVE THYROID EYE DISEASE.”
“Viridian Therapeutics shares dropped sharply after Amgen announced strong results from a Phase 3 clinical trial for its thyroid eye disease (TED) treatment. The positive data strengthens Amgen’s position in the market and raises concerns about increased competition for Viridian, which is developing its own subcutaneous TED therapy, veligrotug (formerly VRDN-001).”
“Investors reacted negatively as Amgen’s progress could impact Viridian’s future market share and commercial potential, especially in a space where treatment innovation and delivery methods (such as subcutaneous vs. intravenous) are key differentiators.”
“Amgen (AMGN) is drawing fresh attention after Phase 3 data for subcutaneous TEPEZZA in Thyroid Eye Disease and strong weight loss results for obesity candidate MariTide reshaped expectations around its specialty and metabolic portfolios.”
“Amgen’s recent TEPEZZA and MariTide updates arrive during a period of solid momentum, with a 90 day share price return of 7.64% and a 1 year total shareholder return of 26.59%, supported by a 3 year total shareholder return of 54.25%.”
“Yet our DCF model, based on future cash flows, points to a fair value of about $650, which implies the current $351 price is at a large discount. When two methods disagree this much, which one do you trust with your own assumptions?”
“However, rising drug pricing pressure and intensifying biosimilar competition around key franchises could still challenge the margin and earnings assumptions behind this fair value case.”
“BeOne Medicines announced on Friday that Chinese officials granted conditional approval for tarlatamab, a bispecific T-cell engager marketed by its U.S. partner Amgen as Imdelltra for a type of lung cancer.”